Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Lung cancer presentation and diagnostic pathway

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise suspected lung cancer promptly and sequence imaging, tissue, staging and fitness assessment so each test answers a treatment decision without avoidable duplication or delay.

  • Persistent or unexplained haemoptysis, cough, breathlessness, chest or shoulder pain, weight loss, hoarseness, clubbing, lymphadenopathy or recurrent focal infection can signal lung cancer.
  • Follow NICE suspected-cancer referral criteria: urgent chest imaging or pathway referral is driven by age, smoking history, symptom combinations and abnormal imaging, not by a single universal presentation.
  • A normal chest radiograph does not exclude central, small or hidden lung cancer when clinical concern persists; review the image and escalate according to the whole presentation.
  • Contrast-enhanced chest CT generally precedes biopsy because it defines the primary lesion, nodes, metastases and the safest procedure likely to diagnose and stage in one sequence.
  • Choose the least invasive test that provides adequate tissue and the highest stage: accessible metastasis, EBUS or EUS, bronchoscopy, image-guided biopsy or surgery each fits a different map.
  • Preserve enough material for histological subclassification, PD-L1 and genomic testing when non-small-cell lung cancer is possible; inadequate tissue can delay or misdirect systemic treatment.
  • Staging intensity should match potentially curative treatment: PET-CT, invasive nodal sampling and brain imaging are chosen because their results would change the plan.
  • Assess performance status, comorbidity, lung function, frailty and the patient's priorities in parallel with diagnosis, while urgently treating haemoptysis, superior vena cava obstruction or spinal cord compression.

Key red flags

Life-threatening haemoptysis requires airway, oxygenation, haemodynamic resuscitation and urgent interventional or surgical coordination before the routine diagnostic sequence.

New limb weakness, sphincter change or severe spinal pain suggests metastatic cord compression and requires the emergency pathway without waiting for lung histology.

Facial and upper-limb swelling with venous distension suggests superior vena cava obstruction; assess airway or cerebral compromise urgently and coordinate imaging and tissue with oncology.

Confusion, dehydration or arrhythmia with hypercalcaemia, or seizures with severe hyponatraemia, needs acute metabolic management while the underlying cancer is investigated.

Do not delay a time-critical emergency treatment solely to obtain an ideal biopsy, but whenever feasible secure diagnostic tissue before therapy that could erase pathological yield.

Investigation priorities

01
Chest radiographFirst step

Provide rapid initial imaging for symptom-triggered suspected lung cancer.

Management branches

SUSPECTMove from symptom to urgent assessment

NICE referral criteria, concerning persistent symptoms, abnormal chest imaging or a compatible paraneoplastic syndrome.

  1. Take a focused symptom, smoking and occupational history, examine for nodes, effusion, collapse, clubbing and metastatic or emergency features, and review prior imaging.
  2. Apply current NICE NG12 criteria for urgent radiography or suspected-cancer referral, documenting why persistent concern remains if the initial chest radiograph is normal.
  3. Request contrast CT through the lung pathway before invasive sampling unless an emergency or readily accessible metastatic site changes the safest sequence.
  4. Give the patient a named contact, safety-net worsening haemoptysis or neurological symptoms, and address distress and smoking support without delaying investigation.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 Suspected cancer recognition and referralCurrent symptom, imaging and urgent referral criteria for lung cancer.
  • NICE NG122 Diagnosis and stagingCT, biopsy selection, nodal staging, PET-CT and fitness assessment.
  • NICE QS17 Lung cancer quality standardCoordinated diagnosis, staging, information and specialist support.
  • NHS England National Genomic Test DirectoryCurrent genomic tests commissioned for cancer pathways.
  • NHS England National Genomic Test Directory overviewGovernance and updating of nationally available genomic testing.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom